keyword
MENU ▼
Read by QxMD icon Read
search

lung cancer, non small cell lung cancer, prognostic markers

keyword
https://www.readbyqxmd.com/read/28638464/overexpression-of-pak1-correlates-with-aberrant-expression-of-emt-markers-and-poor-prognosis-in-non-small-cell-lung-cancer
#1
Zhiying Yang, Heran Wang, Longzheng Xia, Linda Oyang, Yujuan Zhou, Baihua Zhang, Xiaoyan Chen, Xia Luo, Qianjin Liao, Jianping Liang
Objective: p21-activated kinases (PAKs) are serine/threonine protein kinases. PAK1 and epithelial-mesenchymal transition (EMT) are key therapeutic targets in cancer. The clinical significance of PAK1 and its potential association with EMT phenotype in non-small cell lung cancer (NSCLC) was investigated. Methods: Immunohistochemistry was used to detect the expression of PAK1, and mesenchymal and epithelial markers (vimentin, N-cadherin, and E-cadherin) in 186 cases of NSCLC tissues and 50 cases of tumor-adjacent normal tissues...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/28638459/towards-prognostic-profiling-of-non-small-cell-lung-cancer-new-perspectives-on-the-relevance-of-polo-like-kinase-1-expression-the-tp53-mutation-status-and-hypoxia
#2
Jolien Van den Bossche, Christophe Deben, Ken Op de Beeck, Vanessa Deschoolmeester, Christophe Hermans, Ines De Pauw, Julie Jacobs, Paul Van Schil, Jan Baptist Vermorken, Patrick Pauwels, Marc Peeters, Filip Lardon, An Wouters
Background: Currently, prognosis of non-small cell lung cancer (NSCLC) patients is based on clinicopathological factors, including TNM stage. However, there are considerable differences in patient outcome within a similar staging group, even when patients received identical treatments. In order to improve prognostic predictions and to guide treatment options, additional parameters influencing outcome are required. Polo-like kinase 1 (Plk1), a master regulator of mitotic cell division and the DNA damage response, is considered as a new potential biomarker in this research area...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/28617550/prognostic-and-diagnostic-significance-of-long-non-coding-rna-agap2-as1-levels-in-patients-with-non-small-cell-lung-cancer
#3
K-J Fan, Y Liu, B Yang, X-D Tian, C-R Li, B Wang
OBJECTIVE: The purpose of this study was to explore whether long non-coding RNA AGAP2-AS1 (AGAP2-AS1) could serve as a novel biomarker for non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Cancer and matched normal lung tissues were collected from 198 patients. AGAP2-AS1 levels were examined by RT-PCR, and the associations of AGAP2-AS1 levels with clinicopathological characteristics evaluated. Overall survival was evaluated using the Kaplan-Meier method...
May 2017: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/28612596/prognostic-value-of-the-neutrophil-to-lymphocyte-ratio-nlr-in-lung-cancer-cases
#4
Berna Akinci Ozyurek, Tugce Sahin Ozdemirel, Sertac Buyukyaylaci Ozden, Yurdanur Erdogan, Bekir Kaplan, Tugba Kaplan
Haemogram assessment is a cheap and easy method which can be readily performed for almost all patients. Leucocyte, neutrophil and lymphocyte counts and the neutrophil to lymphocyte ratio (NLR) are markers of systemic inflammation. We here aimed to evaluate haemogram parameters of our patients with lung cancer according to the pathologic diagnosis of small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Materials and Methods: The study included 386 patients diagnosed with lung cancer in our hospital between January 2006 and January 2014...
May 1, 2017: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/28610956/upregulation-of-microrna-137-expression-by-slug-promotes-tumor-invasion-and-metastasis-of-non-small-cell-lung-cancer-cells-through-suppression-of-tfap2c
#5
Tzu-Hua Chang, Meng-Feng Tsai, Chien-Hung Gow, Shang-Gin Wu, Yi-Nan Liu, Yih-Leong Chang, Sung-Liang Yu, Hsing-Chen Tsai, Shih-Wen Lin, Yen-Wei Chen, Po-Yen Kuo, Pan-Chyr Yang, Jin-Yuan Shih
The epithelial-mesenchymal transition (EMT) regulator, Slug, plays multifaceted roles in controlling lung cancer progression, but its downstream targets and mechanisms in promoting lung cancer progression have not been well defined. In particular, the miRNAs downstream of Slug in non-small cell lung cancer (NSCLC) remain undetermined. Here, we report that miR-137 is downstream of the EMT regulator, Slug, in lung cancer cells. Slug binds directly to the E-box of the miR-137 promoter and up-regulates its expression in lung cancer cells...
June 10, 2017: Cancer Letters
https://www.readbyqxmd.com/read/28602126/clinical-and-prognostic-significance-of-lupus-anticoagulant-measurement-in-patients-with-lung-cancer
#6
Xianming Fei, Huan Wang, Lei Jiang, Tongwei Zhao, Maoliang Cheng, Wufeng Yuan
Lupus anticoagulants is related to both recurrent thrombosis and cancer. Thrombotic complications occur more frequently in patients with lung cancer. The aim of this study is to investigate the association of lupus anticoagulants with hypercoagulability and thrombotic complications, as well as prognostic significance of lupus anticoagulants for patients with lung cancer. The study comprised 205 patients with non-small cell lung cancer. Plasma normalized LAC ratio, D-dimer, fibrinogen, activities of antithrombin, and FVIII before treatment were analyzed by coagulation analyzer, and routine hematologic and biochemical parameters were also evaluated...
January 1, 2017: Technology in Cancer Research & Treatment
https://www.readbyqxmd.com/read/28596508/promoter-hypomethylation-of-ny-eso-1-association-with-clinicopathological-features-and-pd-l1-expression-in-non-small-cell-lung-cancer
#7
Anderly C Chüeh, Mun-Sem Liew, Prudence A Russell, Marzena Walkiewicz, Aparna Jayachandran, Maud H W Starmans, Paul C Boutros, Gavin Wright, Stephen A Barnett, John M Mariadason, Thomas John
Cancer-Testis antigens (CTA) are immunogenic molecules with normal tissue expression restricted to testes but with aberrant expression in up to 30% of non-small cell lung cancers (NSCLCs). Regulation of CTA expression is mediated in part through promoter DNA methylation. Recently, immunotherapy has altered treatment paradigms in NSCLC. Given its immunogenicity and ability to be re-expressed through demethylation, NY-ESO-1 promoter methylation, protein expression and its association with programmed death receptor ligand-1 (PD-L1) expression and clinicopathological features were investigated...
May 23, 2017: Oncotarget
https://www.readbyqxmd.com/read/28539467/b7-h3-expression-in-nsclc-and-its-association-with-b7-h4-pd-l1-and-tumor-infiltrating-lymphocytes
#8
Mehmet Altan, Vasiliki Pelekanou, Kurt A Schalper, Maria I Toki, Patricia Gaule, Konstantinos N Syrigos, Roy S Herbst, David L Rimm
Background and Purpose: <p>The immune checkpoint PD-1 and its receptor B7-H1 (PD-L1) are successful therapeutic targets in cancer but less is known about other B7 family members.  Here, we determined the expression level of B7-H3 protein in non-small cell lung cancer (NSCLC) and evaluated its association with tumor infiltrating lymphocytes (TILs), PD-L1, B7-H4 and major clinico-pathological characteristics is in 3 NSCLC cohorts.</p> <p>Experimental design:</p> <p>We used multiplexed automated quantitative immunofluorescence (QIF) to assess the levels of B7-H3, PD-L1, B7-H4 and TILs in 634 NSCLC cases with validated antibodies...
May 24, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28534966/microrna-92a-promotes-epithelial-mesenchymal-transition-through-activation-of-pten-pi3k-akt-signaling-pathway-in-non-small-cell-lung-cancer-metastasis
#9
Chaojing Lu, Zhengxiang Shan, Jiang Hong, Lixin Yang
MicroRNAs (miRNAs) have important roles in various cancers, including non-small cell lung cancer (NSCLC). Although several miRNAs have reported to be involved in the development of NSCLC, understanding the regulatory roles of other miRNAs in NSCLC is essential. Therefore, the aim of the current study was to explore the roles and mechanisms of screened miRNAs in NSCLC. First, the differentially expressed miRNAs that were screened based on GSE29248 microarray data retrieved from Gene Expression Omnibus (GEO)...
May 16, 2017: International Journal of Oncology
https://www.readbyqxmd.com/read/28533476/neutrophil-lymphocyte-ratio-is-a-prognostic-marker-in-patients-with-locally-advanced-stage-iiia-and-iiib-non-small-cell-lung-cancer-treated-with-combined-modality-therapy
#10
Katherine A Scilla, Søren M Bentzen, Vincent K Lam, Pranshu Mohindra, Elizabeth M Nichols, Melissa A Vyfhuis, Neha Bhooshan, Steven J Feigenberg, Martin J Edelman, Josephine L Feliciano
BACKGROUND: Neutrophil-lymphocyte ratio (NLR) is a measure of systemic inflammation that appears prognostic in localized and advanced non-small cell lung cancer (NSCLC). Increased systemic inflammation portends a poorer prognosis in cancer patients. We hypothesized that low NLR at diagnosis is associated with improved overall survival (OS) in locally advanced NSCLC (LANSCLC) patients. PATIENTS AND METHODS: Records from 276 patients with stage IIIA and IIIB NSCLC treated with definitive chemoradiation with or without surgery between 2000 and 2010 with adequate data were retrospectively reviewed...
June 2017: Oncologist
https://www.readbyqxmd.com/read/28521472/cd117-expression-is-a-predictive-marker-for-poor-prognosis-in-patients-with-non-small-cell-lung-cancer
#11
Tomohiko Sakabe, Junya Azumi, Tomohiro Haruki, Yoshihisa Umekita, Hiroshige Nakamura, Goshi Shiota
Non-small cell lung cancer (NSCLC) accounts for >85% of incidences of lung cancer, for which the predicted 5-year survival rates are low and recurrence rates remain high. Although it has been reported that the patients with SCLC cells that possess the cluster of differentiation (CD) 117 marker exhibited poor prognosis and poor response to chemotherapy, no studies concerning the association of CD117 expression with prognosis of the patients with NSCLC have been reported. An in vitro study reportedly revealed that CD117-positive cell populations in NSCLC cell lines exhibited cancer stem cell (CSC) phenotypes including self-renewal and chemoresistance...
May 2017: Oncology Letters
https://www.readbyqxmd.com/read/28515924/effect-of-serum-interleukin-1-receptor-antagonist-level-on-survival-of-patients-with-non-small-cell-lung-cancer
#12
Murat Yigit, Serkan Değirmencioğlu, Erhan Ugurlu, Arzu Yaren
Due to poor prognosis in advanced non-small cell lung cancer (NSCLC), new effective markers are required in the monitoring of the disease. The present study aimed to investigate the association between the serum IL-1 receptor antagonist (IL-1Ra) level, overall survival (OS), and treatment response in NSCLC, and to evaluate the usefulness of the serum IL-1Ra level as a prognostic marker for NSCLC. Eighty patients (72 men and 8 women) and 40 healthy volunteers (13 men and 27 women) were included in the present study...
May 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28514746/diagnostic-and-prognostic-values-of-endothelial-cell-specific-molecule-1-with-malignant-pleural-effusions-in-patients-with-non-small-cell-lung-cancer
#13
Guo-Jun Lu, Cheng-Jie Shao, Yu Zhang, Yong-Yue Wei, Wei-Ping Xie, Hui Kong
Over-expressed endothelial-cell-specific molecule-1 (ESM-1) in tumor vascular endothelium contributes to tumor angiogenesis, metastasis, and poor prognosis. However, the content of ESM-1 in pleural effusion is unclear. A retrospective study was carried out to investigate the diagnostic and prognostic values of ESM-1 with malignant pleural effusions in patients with non-small cell lung cancer (NSCLC). ESM-1 levels in malignant pleural effusion (MPE) from 70 patients with NSCLC and 50 cases of benign pleural effusion (BPE) were measured using enzyme-linked immunosorbent assay...
April 27, 2017: Oncotarget
https://www.readbyqxmd.com/read/28499650/the-mesenchymal-state-predicts-poor-disease-free-survival-in-resectable-non-small-cell-lung-cancer
#14
Kunal Mehta, Erika Moravcikova, David McFall, James D Luketich, Arjun Pennathur, Albert D Donnenberg, Vera S Donnenberg
BACKGROUND: The epithelial-mesenchymal transition (EMT) is thought to contribute to the overall invasiveness of malignant cells. Expression of cluster of differentiation (CD) 44 and CD90 mark the mesenchymal state in multiple epithelial malignancies. Their role in lung cancer remains unclear, however. This study evaluated the prognostic significance of CD44 and CD90 coexpression in patients with resectable primary non-small cell lung cancer (NSCLC). METHODS: This was a nonconcurrent cohort study of patients with resectable NSCLC, stratified by the degree of expression of CD44/CD90 double-positive cells in their primary tumor...
July 2017: Annals of Thoracic Surgery
https://www.readbyqxmd.com/read/28497423/validation-of-the-prognostic-value-of-new-sub-stages-within-the-ajcc-8th-edition-of-non-small-cell-lung-cancer
#15
O Abdel-Rahman
BACKGROUND: The 8th edition of the American Joint Committee on Cancer (AJCC) staging system for non-small cell lung cancer (NSCLC) has been released. The current study tried to validate the prognostic significance of the new system among patients registered within the surveillance, epidemiology and end results (SEER) database. METHODS: SEER database (2010-2013) has been accessed through SEER*Stat program and AJCC 8th edition stages were reconstructed utilizing the collaborative stage descriptions...
May 11, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28490471/analysis-of-prognostic-values-of-various-pet-metrics-in-preoperative-fdg-pet-for-early-stage-bronchial-carcinoma-for-progression-free-and-overall-survival-significantly-increased-glycolysis-is-a-predictive-factor
#16
Seraina Steiger, Michael Arvanitakis, Beate Sick, Walter Weder, Sven Hillinger, Irene A Burger
Purpose: To assess various volume based PET quantification metrics including: metabolic tumor volume (MTV) and total lesion glycolysis (TLG) with different thresholds as well as background activity based PET metrics (Background Subtracted Lesion activity (BSL) and Volume (BSV)) as prognostic markers for progression free and overall survival (PFS, OS) in early stage I and II non-small cell lung cancer (NSCLC) after resection. Patients and Methods: 133 patients received an adequate FDG PET/CT scan prior to surgery between January 2003 and December 2010...
May 10, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28487765/the-long-term-prognosis-of-induction-chemotherapy-followed-by-surgery-for-n2-non-small-cell-lung-cancer-a-retrospective-case-series-study
#17
Naohiro Taira, Hidenori Kawasaki, Tomonori Furugen, Takaharu Ichi, Kazuaki Kushi, Tomofumi Yohena, Tsutomu Kawabata
INTRODUCTION: The long-term prognosis of induction chemotherapy followed by surgery for N2 non-small lung cell cancer (NSCLC) remains controversial. PATIENTS AND METHODS: We retrospectively reviewed the data and assessed the prognosis of 31 N2-NSCLC patients who underwent induction chemotherapy followed by surgery at our institution between January 1999 and December 2013. Potential prognostic factors, such as age, gender, tumor histology, tumor marker levels, tumor size, the number of N2 lymph nodes, the time from the last induction chemotherapy to the date of surgery, induction chemotherapy, RECIST response, downstaging status, pathological stage, adjuvant chemotherapy, and EF, were analyzed...
May 2017: Annals of Medicine and Surgery
https://www.readbyqxmd.com/read/28474575/circulating-tumor-cells-predict-prognosis-following-tyrosine-kinase-inhibitor-treatment-in-egfr-mutant-non-small-cell-lung-cancer-patients
#18
Baohong Yang, Aiying Qin, Kongyuan Zhang, Haipeng Ren, Shuzhen Liu, Xiaolei Liu, Xiangpo Pan, Guohua Yu
Epithelial growth factor receptor (EGFR) mutations are present in 10-26% of non-small-cell lung cancer (NSCLC) tumors and are associated with response to tyrosine kinase inhibitors (TKIs). This study aimed to detect and quantify the presence of circu-lating tumor cells (CTCs) in EGFR-mutant NSCLC patients and investigate their possi-ble role in providing prognostic information. Enrolled patients received erlotinib 150 mg or gefitinib 250 mg orally once daily as first line treatment. Serial blood samples were taken at baseline (CTC-d0), and on day 28 (CTC-d28) following the initiation of erlo-tinib/gefitinib for detection of CTCs using the CellSearch system...
April 25, 2017: Oncology Research
https://www.readbyqxmd.com/read/28469508/effects-of-serum-leptin-and-resistin-levels-on-cancer-cachexia-in-patients-with-advanced-stage-non-small-cell-lung-cancer
#19
Gökcen Demiray, Serkan Değirmencioğlu, Erhan Uğurlu, Arzu Yaren
INTRODUCTION: Cancer cachexia is one of the most frequent effects of malignancy, is often associated with poor prognosis, and may account for up to 20% of cancer deaths. The aim of our study was to evaluate the relationship of cancer cachexia and serum levels of resistin and leptin in patients with advanced non-small cell lung cancer. METHODS: A total of 67 chemotherapy-naïve patients with advanced-stage non-small cell cancer and a control group containing 20 healthy individuals without a known chronic disease were enrolled in this study...
2017: Clinical Medicine Insights. Oncology
https://www.readbyqxmd.com/read/28459197/predictive-and-prognostic-value-of-serum-periostin-in-advanced-non-small-cell-lung-cancer-patients-receiving-chemotherapy
#20
Yan Zhang, Dongmei Yuan, Yanwen Yao, Wenkui Sun, Yi Shi, Xin Su
Periostin is an extracellular matrix protein involved in tumorigenesis and metastasis. However, the role of serum periostin as a surrogate marker for treatment efficacy is still unknown. In 122 advanced non-small cell lung cancer cases, 37 patients with benign lung disease and 40 healthy controls, serum periostin was measured by enzyme-linked immunosorbent assays. The associations of serum periostin levels with the clinic-pathological parameters, chemotherapy response, and clinical outcomes of non-small cell lung cancer patients were analyzed...
May 2017: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
keyword
keyword
80881
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"